

Treatment 1	Treatment 2	NMA estimate, odds ratio			NMA estimate, risk difference			Indirect estimate, odds ratio			Direct estimate, odds ratio		
		OR	LCL	UCL	RD	LCL	UCL	OR	LCL	UCL	OR	LCL	UCL
sarilumab	sarilumab, steroids	1.75	1.07	2.92	82.4	12.1	136.9						
sarilumab	standard care/placebo	1.06	0.76	1.49	9.1	-52.1	62.6				1.05	0.68	1.59
sarilumab	steroids	1.34	0.92	2.01	46.7	-14.6	100.4						
sarilumab	tocilizumab	0.97	0.64	1.48	-8.2	-88.4	61.3						
sarilumab	tocilizumab, steroids	1.67	1.09	2.59	76.2	15.0	126.7						
sarilumab, steroids	standard care/placebo	0.61	0.41	0.87	-73.3	-121.2	-22.5						
sarilumab, steroids	steroids	0.76	0.56	1.06	-35.7	-74.2	8.1	0.71	0.44	1.15	0.82	0.49	1.41
sarilumab, steroids	tocilizumab	0.55	0.36	0.85	-90.6	-158.0	-26.4						
tocilizumab, steroids	sarilumab, steroids	1.05	0.77	1.43	6.2	-36.0	43.4	0.96	0.59	1.57	1.12	0.34	3.70
steroids	standard care/placebo	0.79	0.64	0.95	-37.5	-70.3	-8.2	0.35	0.15	0.80	0.84	0.64	1.07
tocilizumab	standard care/placebo	1.09	0.85	1.40	17.3	-25.7	65.5	2.42	1.07	5.59	0.98	0.70	1.36
standard care/placebo	tocilizumab, steroids	1.57	1.20	2.08	67.1	29.0	106.9						
tocilizumab	steroids	1.39	1.03	1.90	54.9	5.9	111.4	1.23	0.89	1.70	2.86	0.75	10.95
tocilizumab, steroids	steroids	0.80	0.67	0.99	-29.6	-55.2	-2.2	0.92	0.50	1.74	0.80	0.64	1.01
tocilizumab	tocilizumab, steroids	1.72	1.21	2.46	84.4	29.5	146.1						

OR, odds ratio; LCL, 95% lower credible limit; UCL, 95% upper credible limit